| Metric | Value | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 525.38 Cr | 1.7% | 30.3% |
| Total Income | 558.78 Cr | 1.2% | 25.6% |
| Expenditure | 443.03 Cr | 5.5% | 37.0% |
| PBT | 115.75 Cr | 38.6% | 4.8% |
| Net Profit | 85.27 Cr | 31.1% | 8.4% |
| OPM | 23.81% | 3.16pp | 2.51pp |
| NPM | 15.26% | 3.48pp | 5.66pp |
| EPS | 8.49 | 29.8% | 7.6% |
Margin Beat Masks the Growth Miss: Profit Fell Despite 30% Revenue Jump
Standalone EBITDA margin beat guidance by 100 bps, but it's a one-time gain from price hikes and inventory. More troubling: consolidated net profit fell 8.4% YoY despite revenue surging 30%. Organic growth of 12.4% trails the trajectory needed to hit FY27 targets.
The paradox: revenue surged, profit fell
Poly Medicure's consolidated revenue jumped 30.3% to ₹525.4 Cr, and reported a net profit of ₹85.3 Cr. On the surface, solid. But net profit fell 8.4% year-on-year—a hard-to-explain gap when revenue is up three full digits. The call explains it: employee costs rose 29% (a Haryana wage hike), and acquisition personnel costs (PendraCare, Citieffe) diluted consolidated net margins. In other words, leverage didn't work. The company invested heavily, added headcount, and the P&L barely moved.
₹525.4 Cr
+30.3% YoY, but +12.4% organic
₹85.3 Cr
-8.4% YoY (vs +30% revenue)
28%
Beats 25–27% guide by 100 bps
₹453.1 Cr
+12.4% YoY (core business)
The margin beat is a mirage
Standalone EBITDA margin came in at 28%, beating the 25–27% guidance range. Management and the street read this as a win. But the call makes clear this is mostly one-time. Standalone gross margin hit 71.5%—a multi-quarter high—due to inventory gains and price hikes taken at the start of the year. Management explicitly guided that this will normalize to 67–69% as the year progresses. The 100-bp beat will fade. The real run-rate margin is in the 25–27% range, which is where guidance sits.
What management claimed vs. what held up
Domestic growth >20%; international >15% (FY27 targets)
Q1 domestic +16.2% (₹146 Cr), international +10% (₹281.8 Cr)
Overstated
Europe recovered to 17–18% organic growth
Europe organic +17.6% in Q1 (on track)
Supported
Standalone EBITDA margin 25–27%; delivered 28%
Standalone EBITDA margin 28% (100 bps above range)
Supported, but transient
Renal business to recover to 15–18% by year-end
Q1 renal -3.8% (₹43.2 Cr). Recovery hinges on antidumping govt decision (pending year-end)
Contradicted; unproven
What changed this quarter
Management reiterated FY27 guidance (consolidated revenue ₹2,300–2,400 Cr, 12.3% growth) despite missing Q1 sub-targets (domestic +16.2% vs >20%, international +10% vs >15%). The playbook: Q1 is seasonally the weakest quarter; recovery is expected Q2 onwards. That's a bet, not a reassurance. On operations: three new leaders joined in the past three months (CEO India/APAC in June, CEO Brazil in August, renal business head). Capacity expansion projects are on track (Faridabad/Palwal facility online by March 2027; Noida facility Q1 FY28). However, cross-selling synergies from acquisitions (PendraCare in cardiology, Citieffe in orthopedics) are now deferred to FY28+ due to CDSCO (Indian regulator) approval cycles. This pushes out margin accretion. Middle East disruption persists. The region saw -32% de-growth in Q1 (vs. +15–20% prior historical growth) due to West Asia conflict; shipping containers are unavailable, and orders are piling at ports. Demand is intact, but the ability to ship is constrained.
The bull-bear ledger
Europe organic growth recovered to 17.6%, matching prior guidance (17–18%). Proof of turnaround in a historically lagging region.
Standalone EBITDA margin beat guidance by 100 bps, signaling pricing power and operational discipline.
FY27 guidance maintained (₹2,300–2,400 Cr consolidated, ₹1,900–2,000 Cr standalone). Management confidence intact.
Cash position strong at ₹855 Cr (no standalone debt). Capex runway clear for Faridabad, Palwal, Noida facilities.
PolyMed 3.0 long-term vision (2x revenue by FY30, 18% CAGR) backed by concrete mechanisms: new leadership, capacity expansion, 25–30 new products/year.
Net profit fell 8.4% YoY despite revenue +30.3%. Leverage and gearing broken; OpEx scaled faster than profit.
Organic revenue growth (12.4%) trails the 15%+ implied by FY27 guidance targets. Domestic and international sub-targets both missed by 4–5 percentage points.
Renal business in free-fall (-3.8% in Q1). Recovery guidance (15–18% by year-end) contingent on government antidumping decision. No control over the outcome.
Standalone margin beat is one-time (price hikes + inventory gains). Run-rate margins (25–27%) will normalize downward from the 28% reported.
Acquisition synergies deferred to FY28+. PendraCare (20% Middle East exposed) currently de-growing. Citieffe growing low-to-mid single digits. No near-term accretion.
Middle East orders stuck at ports (-32% de-growth this quarter). While demand is strong, the logistics bottleneck is choking export revenue.
The street's verdict: price action and ownership
The stock was announced at ₹1,693.8 pre-result. On day 1, it rallied +4.64% with 73.5% delivery on the buy side; by day 3, it had posted +10.37%. The pop has held, suggesting the market bought the margin beat and guidance reiteration. However, the stock is trading at ₹1,786.2—still 14.71% below its all-time high and within its 52-week range (₹1,189–₹2,094.3). It sits above all major moving averages (SMA20, SMA50, SMA200), a technically bullish signal. RSI at 64.3 is neutral (not overbought). Ownership: Foreign institutional investors (FII) are trimming. Q1 FY27 shows FII at 5.57% vs. 5.91% a quarter ago (down 34 basis points). In contrast, they held 11.41% and 9.40% in earlier quarters. This is a strategic withdrawal, not a flash. Domestic institutional investors (DII) are stable at 16.08% (up 49 bps QoQ). Promoters remain locked at 62.42%. The market's read: the margin beat and FY27 guidance maintenance are worth a pop, but the organic growth miss and FII trimming suggest institutions are waiting for Q2 to see if growth can restore. The profit decline is a red flag that's being overlooked in the euphoria over margins.
Ranked risks
Renal business recovery hinges on government antidumping decision
HighRenal is -3.8% YoY and is a material segment (₹43.2 Cr). Management guidance (15–18% recovery by year-end) is fully contingent on a 20% anti-dumping duty being imposed. This is outside management's control and outcome is uncertain.
PAT efficiency deteriorating; leverage broken
HighConsolidated PAT fell 8.4% while revenue rose 30.3%. Employee costs +29%, acquisition OpEx dilution. This signals that the company's ability to convert revenue into profit is deteriorating, not improving. A troubling trend if it persists into FY28.
Organic revenue growth (12.4%) trails FY27 targets
HighTo achieve FY27 guidance of ₹2,300–2,400 Cr consolidated (12.3% growth), organic growth must accelerate to 15%+ in remaining 9 months. Q1 at 12.4% means the hurdle is set high. If Middle East remains disrupted or domestic growth doesn't accelerate, guidance is at risk.
Middle East logistics disruption persists
HighWest Asia conflict has choked shipping. Q1 saw -32% de-growth. Demand is intact, but orders are stuck at ports. If resolution takes months, revenue and cash flow will be impacted.
Standalone margin beat (28%) will normalize to 25–27%, removing a key driver of the day-3 pop
MediumMargin compression from 28% to mid-to-high 25% range (as price hikes and inventory gains fade) will be a negative surprise to the market. This will likely reflect in Q2–Q3 reported margins.
Acquisition synergies delayed to FY28+; near-term accretion muted
MediumPendraCare and Citieffe are not yet contributing materially to growth or margins. Regulatory approval cycles have pushed synergy realization by a year. If synergies disappoint even after FY28, PolyMed 3.0 ambitions are at risk.
The debate
The honest read: Poly Medicure is executing on a long-term vision (PolyMed 3.0), but Q1 is a stumble, not a stride. The margin beat is real but shallow (one-time). The profit decline is the real story—it reveals that the company is not yet harvesting leverage from scale. Management's bet that Q2–Q4 will restore growth momentum is reasonable but unproven. Europe recovery is a green flag; Middle East disruption and renal headwinds are yellow flags. The antidumping decision is a wildcard. The stock's post-result pop (day 3 at +10.37%) reflects euphoria over margins and guidance reiteration. But the structural questions—can organic growth accelerate? Can PAT leverage restore?—remain unanswered. Q2 will be a critical test.
What to watch next
1 · Q2 FY27 earnings (Oct 2026): Domestic & international growth acceleration
The critical test. Q2 needs to show domestic >18%, international >12% to restore confidence in FY27 trajectory. Without momentum, organic growth guidance (15%+) looks unrealistic. Also watch for signs of Middle East orders resuming shipment.
2 · Govt antidumping decision on Chinese dialyzers (expected by end FY27)
Binary outcome. A 20% injury margin ruling would unlock Renal recovery to 15–18% by year-end. No decision or a lower ruling keeps Renal under pressure. This is the key upside/downside driver for FY27 PAT.
3 · Faridabad/Palwal facility operationalization (Q4 FY27); Noida facility online (Q1 FY28)
Capex is ₹200–225 Cr for FY27 (on track). These facilities will drive capacity for orthopedics, transfusion, and cardiology. Early revenue ramp vs. capex depreciation is the margin test for FY28+.
4 · Acquisition synergy materialization timelines (FY28+)
PendraCare and Citieffe must show organic acceleration and margin accretion by FY28. Cross-sell synergies (manufacturing shift to India, new market approvals) are the hidden value. Disappointment here would dim PolyMed 3.0 credibility.
The number to track
Organic revenue growth (ex-acquisitions). Q1 at +12.4% is below the 15%+ needed for FY27 guidance. If Q2–Q4 don't show acceleration back to 14–16%, FY27 guidance will likely be cut in Q3. This is the bellwether. PAT gearing is the second metric—watch whether the 8.4% profit decline reverses or widens in Q2. If profit grows again when revenue accelerates, confidence in the business model restores.
Poly Medicure delivered a quarter of marginal comfort (EBITDA beat, guidance held) but genuine concern (profit down, organic growth missed). The market's +10.37% pop by day 3 is warranted on the margin beat, but it masks unresolved execution questions. Management's bet on Q2–Q4 recovery is not credible without proof. The antidumping decision on Renal is a wildcard. The stance: Hold until Q2 restores growth momentum. If organic growth stays below 13% or PAT declines again, downgrade to Reduce. Europe recovery and PolyMed 3.0 ambition are the long-term case, but near-term execution risk is high. The honest read is a steady business, not a step-change.
Credibility quarter: Can new management establish execution amid ambitious FY27 growth?
POLY MEDICURE reports Q1 FY-2027 under new leadership with ₹1,000 Cr in fresh QIP capital deployed for acquisitions and capacity. Street expects 27% FY27 revenue growth to ₹2,300–2,400 Cr, but recent quarterly misses have tempered confidence. Q1 must validate the transformation thesis.
What matters in Q1 FY27
POLY MEDICURE is in a transformation quarter. The company has pivoted from low-complexity commodity medical devices to higher-margin, high-complexity products (IVL, drug-eluting balloons, cardiovascular platforms) via two major acquisitions financed by a ₹1,000 Cr QIP. New CEO Indranil Mukherjee takes the helm for the first time on results day — he joins from a legacy of delivery in Asia-Pacific markets. Street guidance for FY27 is aggressive: ₹2,300–2,400 Cr revenue (27% growth) and 25–27% EBITDA margins. But analysts have downgraded estimates by 18% following recent quarterly shortfalls. Q1 must prove that management guidance is achievable, not aspirational.
~₹160–180 Cr
Tracking toward FY27 ₹2,300–2,400 Cr annualized run-rate; organic + contribution from recent M&A
~22–25%
Management guides 25–27% for full year; Q1 may reflect acquisition integration drag
~15–20%
FY27 full-year target is 27%; Q1 should show momentum toward that trajectory
On track for FY27?
Management has set a clear compass: ₹2,300–2,400 Cr in consolidated revenue and 25–27% EBITDA margins by end-FY27. This implies a growth arc of ~27% YoY. For that to happen, Q1 needs to establish the momentum. Recent results (FY26 closing at ₹160 Cr standalone) missed analyst expectations and triggered downgrades. Investors are watching whether the QIP deployment into acquisitions (PendraCare for cardiovascular, Citieffe for surgical platforms) can actually drive margin accretion or will dilute near-term profitability due to integration costs. CRISIL reaffirmed AA-/A1+ ratings with a Positive outlook, signaling the agency views the strategy as sound. The Street, however, is skeptical: consensus is a Hold (TrendLyne) to Strong Sell (Bitget), with 12-month target around ₹1,607, implying downside from ₹1,704.8 current. Q1 results will either validate the bull case (FY27 growth, margin recovery) or raise execution risk.
Key expectations: strong vs weak quarter
A strong Q1 would show: (1) Revenue of ~₹180+ Cr, demonstrating 20%+ YoY growth and momentum toward FY27 guidance; (2) EBITDA margin of 24%+, indicating acquisition integration is not materially dragging profitability; (3) Organic growth in core medical device segments holding steady (~15%+ YoY) alongside contribution from Citieffe/PendraCare; (4) Management commentary acknowledging recent misses but reaffirming FY27 trajectory and new-product ramp (35 products already launched, 50+ planned). A weak Q1 would signal: (1) Revenue miss or growth deceleration (<15% YoY) vs the ₹2,300+ Cr annualized path; (2) EBITDA margin contraction to <22%, suggesting acquisition drag or pricing pressure; (3) Management guidance downgrade or qualification on FY27 targets; (4) Continued renal segment softness (analysts have already revised growth expectations down to ~20%) without offsetting strength elsewhere.
Since last quarter: the setup
POLY MEDICURE has been active. In May, the board approved FY26 results (₹1,601.8 Cr revenue, ₹3.5 per-share dividend at 70% payout) and declared no deviation in QIP fund utilization — the ₹1,000 Cr capital is being deployed as planned for acquisitions and capex. On June 1, CEO Indranil Mukherjee joined, signaling a shift toward international scale and operational discipline. The company then embarked on an extensive investor roadshow (June 2–26, multiple meetings with Axis Max Life, T. Rowe Price, HSBC, and others), suggesting management confidence in the transformation story and a desire to rebuild analyst consensus after recent disappointment. A minor legal overhang exists: a ₹2.5 Cr stamp duty and penalty order from Delhi (June 16) was stayed by the Delhi High Court on July 8, so no immediate cash outflow risk. The trading window for insiders closed June 29 in advance of results. All told, the quarter shows execution moving forward, but credibility is thin.
1 · Revenue growth and FY27 trajectory
Does Q1 revenue run at ₹160–180 Cr+ with 15–20% YoY growth, validating the ₹2,300–2,400 Cr FY27 path? Anything below this range invites Street downgrades and reinforces caution. Watch for organic vs. inorganic split — how much is real growth vs. M&A contribution?
2 · EBITDA margin sustainability
Management guides 25–27% full-year margins; Q1 showing 24%+ would signal acquisition integration is healthy. A drop below 22% would raise questions about near-term margin accretion and acquisition synergy timing. This is the credibility test.
3 · New product ramp and segment commentary
With 35 products already launched (target 50+ for FY27), watch for color on adoption, pricing, and mix shift toward higher-margin cardiovascular/specialty platforms. Renal segment softness (growth revised to ~20%) needs offset elsewhere. Any reset in segment guidance or product commentary will move the needle.
POLY MEDICURE is at an inflection. The ₹1,000 Cr QIP, the pivot to high-complexity devices, and a new CEO signal ambition. But the Street has lost faith after recent misses, and consensus price targets suggest 4–28% downside depending on execution. Q1 results — revenue trajectory, margin hold-up, management confidence on FY27 — will either restore belief or entrench skepticism. The new leadership's credibility hinges on delivering on the headline guidance: ₹2,300–2,400 Cr and 25–27% EBITDA margins. Q1 must begin that journey convincingly.
Strong margins mask growth miss; execution risk on 2030 vision
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Guidance reaffirmed despite Q1 miss. Standalone EBITDA beat (margin). Europe recovery on plan (17.6%). Renal recovery unproven; antidumping outcome pending.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Poly Medicure maintained FY27 guidance (₹2,300–2,400 Cr consolidated) despite Q1 missing domestic/international growth targets (16.2%/10% vs 20%/>15%). Margin beat (28% EBITDA vs 25–27%) is transient (inventory + price hikes normalizing to 67–69%). PAT contracted 8.4% YoY despite 30.3% revenue growth—a red flag on operational gearing. Long-term strategy (PolyMed 3.0: 2x by FY30) is credible but execution risk high: leadership changes just joined, Middle East disrupted, renal recovery hinges on government anti-dumping decision. Hold until Q2 shows momentum restore.
₹525.4 Cr
Revenue · +30.3% YoY₹85.3 Cr
Reported PAT · −8.4% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Domestic growth >20%; Q1 domestic up 16.2%
OVERSTATEDQ1 standalone domestic ₹146 Cr, +16.2% YoY (vs 20%+ guidance)
International growth >15%; Q1 international up 10%
OVERSTATEDQ1 standalone international ₹281.8 Cr, +10% YoY (vs 15%+ guidance)
Europe recovered to 17–18% organic growth
METEurope Q1 organic growth 17.6% (on target; vs -prior-year laggard status)
Standalone EBITDA margin 25–27%; delivered 28%
METStandalone EBITDA ₹120.8 Cr on ₹431 Cr revenue = 28.0% (100 bps above range due to price hikes + inventory gains)
Consolidated EBITDA margin 23–25%; delivered 24.1%
METConsolidated EBITDA ₹126.7 Cr on ₹525.4 Cr revenue = 24.1% (within range)
Renal turnaround to 15–18% by year-end (from -3.8% in Q1)
MISSRenal down ₹43.2 Cr, -3.8% YoY; recovery contingent on anti-dumping duty (20% injury margin claimed, decision expected by year-end)
Earnings quality
What changed since the last call
Domestic growth guidance unmet
DowngradeQ1 domestic +16.2% vs >20% FY27 guidance. Mgmt attributes to Q1 seasonal weakness and price hike absorption; expects recovery Q2+. No numeric guidance cut, but trajectory downside noted.
International growth lagging
DowngradeQ1 international +10% vs >15% guidance. Middle East -32% due to West Asia crisis logistics. Europe +17.6% organic recovered (vs prior laggard). Overall organic export +12.4%, below target.
Renal business in distress
DowngradeQ1 renal -3.8% to ₹43.2 Cr. Chinese dumping via ASEAN FTA zero-duty pressure. Anti-dumping probe initiated; recovery to +15–18% contingent on government decision.
Margin normalization flagged
DowngradeStandalone gross margin 71.5% in Q1 will normalize to 67–69% as inventory gains fade and price hikes pass through. Q1 EBITDA margin 28% above 25–27% guidance; expect mid-to-high range going forward.
Synergy timeline pushed out
DowngradePendraCare/Citieffe cross-selling synergies now expected FY28+ (was previously expected to accelerate FY27). Regulatory approval delays cited.
The Q&A
Analysts pressed hard on growth trajectory shortfalls and renal recovery. Mgmt acknowledged Q1 is seasonally lowest and defended guidance by noting price hike absorption and upcoming recovery. Questioned on acquisition performance: Deepak (Sundaram) noted acquired firms showing no growth yet; Rashmee (Dolat) probed synergy timing and EBITDA expansion targets. Mgmt held firm on guidance and blamed geopolitical disruption, regulatory timelines. Overall pushback was constructive; management mostly transparent, occasionally evasive on cost breakups.
Growth trajectory shortfall — Bhavya Gandhi, Bajaj Alternative Investment Managers
PartialQ1 is historically lowest; recovery expected Q2 onwards. Price hike taken at start of year caused initial slowdown; momentum expected to build. Guidance maintained at ₹1,900–2,000 Cr standalone.
Acquisition deployment — Bhavya Gandhi, Bajaj Alternative Investment Managers
AnsweredOrganic + inorganic expansion. Brazil expansion funds (new small acquisition in place). Technologies in cardiology/oncology/orthopedics targeted. Capex for 2 new plants (Faridabad, Noida). Asset turns 1.2–1.4x to continue.
Domestic segment drivers — Sidharth Negandhi, CWC
AnsweredInfusion therapy domestic grew 20%+. Cardiology & critical care (newer segments) grew meaningfully. Renal de-growth of -3.8% offset gains.
Middle East shipping disruption — Sidharth Negandhi, CWC
AnsweredShipping schedule still disrupted; hard to find containers. Demand intact; orders piling at ports. Ships not calling. Disruption continues; hoping for easing in coming weeks.
Acquisition integration — Sidharth Negandhi, CWC
AnsweredIntegration on track. Synergies identified (cost, R&D, sales). Cross-selling expected FY28+ due to CDSCO approval cycles for India market entry.
Growth aspiration calibration — Bharat C. Shah, BCS Capital Ideas
Answered18% CAGR needed. Currently 80% organic, 20% inorganic; expect similar run-rate (14–15% organic, 3–4% inorganic). Margins 25–27% maintained (upper end by year-end); will improve as scale happens but reinvested.
Export growth outlook — Deepak, Sundaram Mutual Fund
PartialEurope (new customer acquisitions, recovery on track). Southeast Asia doing well. U.S. fluid situation. Middle East high-upside once resolved (20–25% potential). 25 new CE-marked products coming in 3–4 months.
Renal recovery — Deepak, Sundaram Mutual Fund
PartialDe-growth due to Chinese dumping via ASEAN FTA. Antidumping probe initiated; 20% injury margin claimed. Decision expected next few months by year-end. New renal head (Abhimanyu Hooda) hired. Expecting 15–18% growth by year-end; possibly 20% depending on probe outcome.
Gross margin trajectory — Deepak, Sundaram Mutual Fund
AnsweredStandalone should normalize to 67–69%. Consolidated 71–72% (due to acquisitions' higher margins). Q1 elevated by inventory gains + price hikes.
Consolidated EBITDA run-rate — Rashmee Shetty, Dolat Capital
AnsweredYes. Consolidated EBITDA guided 23–25%; Q1 delivered 24.1%. OpEx higher due to acquisition nature and scaling. Maintaining guidance.
Acquisition growth — Rashmee Shetty, Dolat Capital
PartialPendraCare 20% Middle East exposed; currently de-growing (West Asia crisis). Citieffe growing mid-to-high single digits. Long-term potential: high single-digit organic growth; mid-teens with synergies, assuming geopolitical resolution.
Debt position — Rashmee Shetty, Dolat Capital
AnsweredStandalone: No debt, only ₹250 Cr working capital revolving credit. PendraCare: No long-term debt. Citieffe: EUR 9 million total, EUR 1.5–2 million annual repayment.
PolyMed 3.0 revenue math — Sidharth Negandhi, CWC
PartialPolyMed standalone will grow faster than subsidiaries directionally. Overall 2x target on consolidated basis. Standalone will outpace acquired entities' growth rates.
Gross margin Q2 outlook — Sidharth Negandhi, CWC
AnsweredMix of price hikes, product mix, inventory gains. Guiding 68–69% gross margin standalone going forward. Some Q2 correction expected vs Q1.
U.S. tariff exposure — Bhavna, NAG Analytics
AnsweredCurrent duty 10%. U.S. exposure small (~USD 3.5–4 million exports). Not a major issue if tariffs rise.
Operating leverage — Bhavya Gandhi, Bajaj Alternative Investment Managers
DodgedManufacturing company; blue-collar workers are variable. Rest fixed (subject to productivity). Mix of both in staff. Tough to give ballpark on call.
Therapy expansion — Girish Jain, KJMC Capital
AnsweredExpand within existing therapies. These are very new (started 1–2 years ago). Regulatory pathways take 2–3 years for Class III devices. Enough on plate. No new therapies substantially expected next few years.
Hospital consumable penetration — Girish Jain, KJMC Capital
AnsweredMarket is huge. Many uncovered therapies (peripheral vascular, neurology, urology, endosurgery, gastroenterology). Significant potential; will build portfolio over time.
Working capital cycle — Girish Jain, KJMC Capital
PartialEurope growth back 17% YoY. Cash conversion cycle: 140 days in March, still ~140 days now. May improve as global situation normalizes, oil prices stabilize.
New product development — Pramod Bhat, Individual Investor
AnsweredPolyMed has 399 global patents. Market leader in infusion/other therapies. Products going to 125 countries based on performance. Differentiation in clinical use (doctor/clinician sees it), not just catalog view. Launching 25–30 products/year.
New facility timelines — Girish Jain, KJMC Capital
AnsweredFaridabad/Palwal: Online by March 2027 (Q4 FY27). Focus orthopedics/transfusion, plus infusion capacity. Noida: Online Q1 FY28. Focus cardio expansion.
Guidance
Consolidated FY27 ₹2,300–2,400 Cr (12.3% growth); maintained
MediumQ1 delivered ₹525.4 Cr (on track for ~23% of annual). Organic growth 12.4% suggests base met; needs Q2–Q4 acceleration to hit 12.3%.
Standalone FY27 ₹1,900–2,000 Cr (15–16% growth); maintained
MediumQ1 ₹431 Cr at 12.3% growth. Domestic >20%, international >15% sub-targets not met in Q1; recovery expected Q2–Q4.
Standalone EBITDA 25–27%; Q1 delivered 28%
MediumQ1 margin 100 bps above range due to price hikes + inventory gains (one-time). Expect normalization to mid-to-high range (26–27%) going forward.
Consolidated EBITDA 23–25%; Q1 delivered 24.1%
HighOn track. Higher-margin acquisitions lifting consolidated profile. Maintained within range.
Gross margin standalone 67–69%; consolidated 71–72%
MediumQ1 standalone 71.5% inflated by inventory/price hikes; normalizes to 67–69%. Consolidated 73.4% (acquisitions' mix benefit).
FY27 capex ₹200–225 Cr; maintained
HighTwo new plants under construction: Faridabad/Palwal (online Mar 2027), Noida (online Q1 FY28). Asset turns 1.2–1.4x to continue.
Risks the call surfaced
Geopolitical & Shipping
HighWest Asia conflict causing 32% de-growth in Middle East Q1. Shipping schedule disrupted; orders piling at ports. Demand intact but unable to ship. Logistics costs up 2–3x over 6 months. Timeline for resolution uncertain.
Competitive & Pricing
HighRenal business -3.8% in Q1 due to Chinese dumping via ASEAN FTA zero-duty imports. Conscious choice to raise prices rather than defend volume. Company has filed antidumping application; injury margin of 20% claimed. Govt decision expected by year-end.
Regulatory & Execution
MediumPendraCare (20% Middle East exposed, currently de-growing) and Citieffe (growing mid-to-high single digits) synergies deferred to FY28+ due to CDSCO approval timelines for cross-sell and manufacturing shift to India. Near-term accretion limited.
Growth & Execution
MediumQ1 domestic +16.2%, international +10% both miss FY27 targets (>20%, >15%). Management attributes to Q1 seasonality but needs sustained acceleration Q2–Q4 to restore trajectory. If growth doesn't recover, FY27 guidance may face downside risk.
Macro & Currency
LowU.S. tariff uncertainty (currently 10% duty). Small direct exposure (USD 3.5–4 million). Hard currency availability in some export markets impacting working capital cycle. Oil price volatility cited.
Management
Score 7/10. Clear on strategic vision (PolyMed 3.0: 2x revenue by FY30). Transparent on challenges (Middle East disruption, Renal competition, logistics costs). Evasive on cost breakups and acquisition-specific euro-denominated growth. Direct on regulatory constraints. Europe recovery on track (17.6% organic = stated 17–18% plan). Acquisition integrations progressing; synergies on hold for CDSCO approvals (FY28+). New leadership just onboarded (Jun/Aug 2026); execution risk remains. Capacity expansion timelines stated (Faridabad Mar 2027, Noida Q1 FY28).
1 · Q2 FY27 (Oct 2026)
Domestic/international acceleration needed to restore >20%/>15% trajectories
2 · End FY27 (Mar 2027)
Govt anti-dumping decision on Chinese dialyzers; 20% injury margin claimed by Poly. Renal recovery hinges on this.
3 · Mar 2027 (Q4 FY27)
Faridabad/Palwal facility online; orthopedics/transfusion capacity expansion begins
Hold until Q2 shows momentum restore.